FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention represents a dosage form for administration at the stage of preobesity, obesity or morbid obesity, containing a compound of one of the structures given below, or a pharmaceutically acceptable salt thereof. Compound is present in a dosage form in a therapeutically effective amount of 0.005 mg to 10 mg per kg of human body weight to stimulate body weight loss, reduce body fat, reduce food consumption, improve glucose homeostasis or a combination of said conditions at the stage of preobesity, obesity or morbid obesity. 
and 
.
EFFECT: invention makes it possible to stimulate weight loss and/or to reduce body fat mass with preobesity, obesity or morbid obesity in the absence of systemic toxicity causing anorexia.
15 cl, 47 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | 2013 |
|
RU2650646C2 |
| CELASTROL AND DERIVATIVES THEREOF FOR TREATING OBESITY | 2015 |
|
RU2706239C2 |
| OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
| NEW N-SULFAMOYLPIPERIDINEAMIDS DESIGNED FOR PREVENTION OR TREATMENT OF FATTY DEGENERATION AND CONGENEROUS PATHOLOGICAL CONDITIONS | 2006 |
|
RU2442773C2 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| AMPK LOW-MOLECULAR ACTIVATORS | 2017 |
|
RU2766146C2 |
| AZOLES AS INHIBITORS OF MALONYL-COA-DECARBOXYLASE USEFUL AS METABOLIC MODULATING AGENTS | 2002 |
|
RU2258706C2 |
| ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
| CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2734261C2 |
